Ozempic for Heart Failure: Off-Label Evidence, Monitoring, and What Clinicians Need to Know

Ozempic Is Not Approved for Heart Failure

Semaglutide carries FDA approval for two distinct indications, and heart failure is not one of them. The 0.5 mg, 1.0 mg, and 2.0 mg weekly doses (branded as Ozempic) are indicated for glycemic control in adults with type 2 diabetes [1]. The 2.4 mg dose (branded as Wegovy) holds a separate approval for chronic weight management and, since March 2024, for reducing cardiovascular events in adults with established cardiovascular disease and obesity [2].

No semaglutide formulation carries an FDA indication for heart failure treatment or symptom management. Prescribers who use Ozempic in heart failure patients are doing so off-label. That distinction matters for insurance coverage, informed consent, and medicolegal documentation. The American Heart Association's 2023 science advisory on GLP-1 receptor agonists in cardiometabolic disease acknowledged the growing evidence base but stopped short of recommending routine use in heart failure outside clinical trials [3].

Off-label prescribing is legal and common in U.S. medicine. Roughly 20% of all prescriptions written in the United States are off-label, according to a 2021 analysis in the Journal of the American Medical Association [4]. The clinical question is not whether off-label use is permissible. It is whether the evidence supports it and whether proper monitoring can mitigate risk.

The STEP-HFpEF Trial Changed the Conversation

Before STEP-HFpEF, GLP-1 receptor agonist data in heart failure were limited to secondary analyses and small mechanistic studies. STEP-HFpEF (N=529) was the first dedicated randomized controlled trial testing semaglutide 2.4 mg weekly against placebo in patients with HFpEF and a BMI of 30 or higher [5].

The results were striking. At 52 weeks, patients receiving semaglutide had a 7.8-point greater improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) compared to placebo (95% CI: 4.8 to 10.9; P<0.001) [5]. They also lost 10.7% of body weight versus 3.1% with placebo. The 6-minute walk distance increased by 21.5 meters more in the semaglutide group. C-reactive protein, a marker of systemic inflammation, dropped by 43.5% [5].

"These findings indicate that treatment with semaglutide led to larger reductions in symptoms and physical limitations and greater improvements in exercise function than placebo," wrote Dr. Mikhail Kosiborod and colleagues in the New England Journal of Medicine [5].

A companion trial, STEP-HFpEF DM (N=616), confirmed similar benefits specifically in patients who also had type 2 diabetes. The KCCQ-CSS improvement was 7.3 points greater with semaglutide, and body weight decreased by 6.4% versus 1.5% [6]. These patients represent the overlap population where on-label diabetes treatment and off-label cardiac benefit may converge.

SELECT Trial: Cardiovascular Risk Reduction Without Heart Failure as a Primary Endpoint

The SELECT trial (N=17,604) enrolled adults with established atherosclerotic cardiovascular disease, a BMI of 27 or greater, and no diabetes [7]. Semaglutide 2.4 mg weekly reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% compared to placebo (HR 0.80; 95% CI: 0.72 to 0.90; P<0.001) [7].

Heart failure was a prespecified secondary outcome. SELECT showed a 18% reduction in the composite of heart failure events (HR 0.82; 95% CI: 0.71 to 0.96) [7]. That signal is hypothesis-generating rather than definitive. SELECT was not powered to detect heart failure outcomes as a standalone endpoint.

The distinction between these two evidence streams matters for clinical decision-making. STEP-HFpEF provides moderate-quality evidence (GRADE B) that semaglutide improves HFpEF symptoms in patients with obesity. SELECT provides evidence for cardiovascular event prevention in a broader population that includes, but is not limited to, patients with heart failure.

Which Heart Failure Patients Might Benefit

Not all heart failure is the same, and the evidence for semaglutide does not apply uniformly across the syndrome. The data are strongest for a specific phenotype.

Patients most likely to benefit share these characteristics: HFpEF (ejection fraction ≥50%), BMI of 30 or above, and symptom burden driven partly by excess adiposity and systemic inflammation [5][6]. The obesity-HFpEF phenotype accounts for an estimated 50 to 80% of HFpEF cases in the United States, based on registry data from the TOPCAT and PARAGON-HF trials [8].

Patients who are less likely to benefit, or in whom evidence is absent, include those with heart failure with reduced ejection fraction (HFrEF, EF <40%), those with a normal BMI, and those whose heart failure is driven primarily by valvular disease, infiltrative cardiomyopathy, or constrictive physiology. The FIGHT trial (liraglutide in HFrEF, N=300) showed no benefit and a trend toward more adverse events with GLP-1 agonist therapy in reduced EF patients [9]. That finding has not been replicated with semaglutide, but it raises a caution flag that clinicians should not ignore.

Monitoring Requirements for Off-Label Cardiac Use

Structured monitoring is the difference between responsible off-label prescribing and guesswork. No published guideline provides a consensus monitoring protocol for semaglutide in heart failure specifically, so the following framework draws from cardiology society recommendations for HFpEF management and the monitoring approaches used in STEP-HFpEF [5][10].

Baseline assessments before initiation:

A transthoracic echocardiogram confirming EF ≥50% and ruling out significant valvular disease should be documented within six months of starting therapy. NT-proBNP (or BNP) provides a baseline biomarker reference point. Renal function (eGFR, serum creatinine) and HbA1c are necessary to screen for diabetes, chronic kidney disease, and volume status. Body weight and a standardized symptom assessment using the KCCQ or equivalent tool complete the baseline picture [10].

During titration (weeks 0 to 16):

Ozempic is titrated from 0.25 mg to 0.5 mg at week 4, then to 1.0 mg at week 8, with an optional increase to 2.0 mg at week 12 if tolerated. During this period, check NT-proBNP and body weight every 4 weeks. A rising NT-proBNP level (increase >30% from baseline) during titration warrants evaluation for worsening heart failure, volume overload, or an intercurrent illness. Diuretic doses may need adjustment as weight loss changes volume status [10].

GI symptoms (nausea, vomiting, diarrhea) occurred in 45.5% of semaglutide-treated patients in STEP-HFpEF versus 27.3% on placebo [5]. For heart failure patients, persistent vomiting or diarrhea can cause dehydration and electrolyte disturbances that destabilize hemodynamics. Potassium, magnesium, and renal function should be rechecked if GI symptoms last longer than 72 hours.

Maintenance monitoring (after dose stabilization):

Once on a stable dose, reassess NT-proBNP and symptoms every 8 to 12 weeks for the first year. Repeat echocardiography at 6 to 12 months to evaluate for changes in diastolic function, left atrial volume, and estimated filling pressures. The STEP-HFpEF investigators reported improvements in echocardiographic parameters including E/e' ratio and left atrial volume index with semaglutide [5].

Biomarkers to Track and What They Mean

NT-proBNP is the most informative single biomarker for monitoring semaglutide's cardiac effects. In STEP-HFpEF, semaglutide reduced NT-proBNP by a treatment ratio of 0.80 (95% CI: 0.70 to 0.92) compared to placebo at 52 weeks [5]. That 20% relative reduction parallels the magnitude seen with some guideline-directed HFpEF therapies.

C-reactive protein (CRP) dropped substantially in both STEP-HFpEF and SELECT, suggesting that part of semaglutide's cardiac benefit operates through anti-inflammatory pathways rather than weight loss alone [5][7]. Tracking CRP at baseline and every 6 months offers a window into systemic inflammation, though it should not drive prescribing decisions on its own.

HbA1c matters even in non-diabetic patients. Semaglutide's glucose-lowering effects can cause hypoglycemia risk when combined with insulin or sulfonylureas. For heart failure patients on complex medication regimens, monitoring HbA1c every 3 months during the first year helps detect unexpected glycemic shifts.

"NT-proBNP reduction with semaglutide in HFpEF was directionally consistent with the improvements in clinical symptoms and physical function," noted the STEP-HFpEF investigators in their supplementary analysis [5].

Drug Interactions and Medication Adjustments

Heart failure patients are typically on multiple medications. Semaglutide's effects on gastric emptying and body weight can alter the pharmacokinetics and clinical effects of several drug classes.

Diuretics. Weight loss of 10% or more often reduces the need for loop diuretics. Continuing pre-treatment diuretic doses without adjustment can lead to volume depletion, orthostatic hypotension, and acute kidney injury. Monitor daily weights and standing blood pressures, and reduce diuretic doses proactively when weight loss exceeds 5% [10].

SGLT2 inhibitors. Dapagliflozin and empagliflozin are now guideline-directed therapy for HFpEF [10]. Combining an SGLT2 inhibitor with semaglutide amplifies weight loss, glycemic lowering, and diuretic effects. No dedicated interaction trial exists, but the combination was permitted in STEP-HFpEF and appeared safe. Monitor renal function and volume status more frequently when both are used.

Insulin. Semaglutide significantly reduces insulin requirements. The Ozempic label recommends considering a reduction in insulin dose when initiating therapy to reduce hypoglycemia risk [1]. For heart failure patients, hypoglycemia can trigger arrhythmias and exacerbate symptoms.

Warfarin. Semaglutide slows gastric emptying, which can affect the absorption profile of oral anticoagulants. INR should be checked more frequently during the first 8 weeks of semaglutide initiation or dose escalation [1].

Safety Signals Specific to Heart Failure

GI adverse events are the dominant safety concern with all GLP-1 receptor agonists, and heart failure adds a layer of risk. In STEP-HFpEF, serious adverse events occurred in 18.4% of semaglutide patients versus 22.7% on placebo, suggesting no excess serious harm [5]. But the 45.5% rate of any GI adverse event is high for a population that may already be managing appetite changes, gut edema, and medication-related nausea from other drugs [5].

Pancreatitis remains a labeled warning for all GLP-1 receptor agonists. The absolute risk is low (approximately 0.1 to 0.3% in clinical trials), but heart failure patients on multiple medications may have overlapping risk factors [1]. Serum lipase should be checked if abdominal pain develops.

Heart rate increases of 2 to 4 beats per minute are consistently observed with semaglutide across trials [1][7]. For most HFpEF patients, this is clinically insignificant. For patients with atrial fibrillation, however, the small chronotropic effect may compound rate control challenges. Monitor resting heart rate at each visit.

Thyroid C-cell tumor risk (boxed warning, based on rodent data) has not translated into a confirmed human signal across large semaglutide trials, but the warning stands for all GLP-1 agonists. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not receive semaglutide [1].

Building a Monitoring Protocol: A Practical Checklist

An organized monitoring schedule reduces the risk of missing early warning signs while avoiding unnecessary testing.

Week 0 (baseline): Echocardiogram, NT-proBNP, CRP, BMP (including potassium, magnesium, creatinine), HbA1c, lipase, TSH, weight, KCCQ score, medication reconciliation, diuretic dose documentation.

Weeks 4, 8, 12, 16 (titration phase): NT-proBNP, weight, blood pressure (sitting and standing), renal panel if GI symptoms present, GI symptom assessment, diuretic dose adjustment as needed.

Months 6 and 12: Repeat echocardiogram, NT-proBNP, CRP, HbA1c, full metabolic panel, KCCQ, medication reconciliation. Evaluate whether ongoing therapy is producing measurable benefit.

Annually thereafter: Echocardiogram, NT-proBNP, CRP, HbA1c, comprehensive metabolic panel, KCCQ, reassessment of indication and continued off-label justification.

Documentation and Informed Consent for Off-Label Prescribing

Off-label prescribing of semaglutide for heart failure requires clear documentation in the medical record. The chart should state the rationale for off-label use, the specific evidence supporting the decision (citing STEP-HFpEF or SELECT as appropriate), and that the patient understands the treatment is not FDA-approved for this condition.

Informed consent should address the off-label nature of the prescription, the evidence base (moderate quality, limited to specific HFpEF phenotypes), common adverse effects (GI symptoms in nearly half of patients), and the monitoring schedule. Patients should know that insurance coverage may be denied or require prior authorization with supporting clinical documentation.

The American Medical Association's guidelines on off-label prescribing recommend that physicians document the scientific rationale and discuss risks and benefits with the patient before initiating therapy [4]. For a YMYL (Your Money or Your Life) decision like adding a non-approved drug to a heart failure regimen, this documentation is both clinically appropriate and legally protective.

What the Ongoing Trials Will Tell Us

Several active trials will clarify semaglutide's role in heart failure within the next 2 to 3 years. The SUMMIT trial (tirzepatide in HFpEF, N=731) reported positive topline results in 2024, showing that dual GIP/GLP-1 receptor agonism also improves HFpEF outcomes [11]. Head-to-head comparisons between semaglutide and tirzepatide in heart failure populations are not yet underway but are anticipated.

The Heart Failure Association of the European Society of Cardiology updated its 2023 position statement to acknowledge GLP-1 receptor agonists as a "promising therapeutic avenue for obesity-related HFpEF" while cautioning that definitive guideline recommendations await larger outcomes trials with heart failure hospitalization or cardiovascular death as primary endpoints [12]. Until those data arrive, off-label semaglutide use in HFpEF should be treated as an evidence-informed clinical decision, not a standard-of-care mandate.

Patients starting off-label semaglutide for HFpEF should have their first NT-proBNP reassessment at 4 weeks, with echocardiographic follow-up no later than 12 months [5][10].